
BioCentury製作的BioCentury This Week
BioCentury
分类: 科學與醫學
新增至我的清單
听听最后一集:
This year’s Bio€quity Europe conference — the 25th edition of the event — will focus on what’s next for Europe amid biotech’s current complex moment, Editor in Chief Simone Fishburn said on a special edition of the BioCentury This Week podcast previewing the meeting, which kicks off May 12 in Bruges, Belgium. McKinsey & Co.’s Alexandra Zemp and Henk Joos, an investment specialist at Medvia, which fosters health innovation in Flanders, joined BioCentury to discuss the state of Belgium’s bi...
以前的剧集
-
305 - Ep. 295 - Bio€quity Europe 2025 Preview Thu, 08 May 2025
-
304 - Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing Mon, 05 May 2025
-
303 - Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs Mon, 28 Apr 2025
-
302 - Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview Fri, 25 Apr 2025
-
301 - Ep. 291 - Grand Rounds - U.S. Preview Thu, 24 Apr 2025
-
300 - Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed Mon, 21 Apr 2025
-
299 - Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA Mon, 14 Apr 2025
-
298 - Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview Mon, 07 Apr 2025
-
297 - Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI Mon, 31 Mar 2025
-
296 - Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs Mon, 24 Mar 2025
-
295 - Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play Mon, 17 Mar 2025
-
294 - Ep. 284 - Takeaways from the East-West Summit Tue, 11 Mar 2025
-
293 - Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI Mon, 10 Mar 2025
-
292 - Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity Mon, 03 Mar 2025
-
291 - Ep. 281 - Roche Reboot and 5 Things on Trump 2.0 Mon, 24 Feb 2025
-
290 - Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs Tue, 18 Feb 2025
-
289 - Ep. 279 - East-West Summit Preview Fri, 14 Feb 2025
-
288 - Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine Mon, 10 Feb 2025
-
287 - Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug Mon, 03 Feb 2025
-
286 - Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler Fri, 31 Jan 2025
-
285 - Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH Mon, 27 Jan 2025
-
284 - Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI Tue, 21 Jan 2025
-
283 - Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds Thu, 16 Jan 2025
-
282 - Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma Mon, 13 Jan 2025
-
281 - Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure Mon, 06 Jan 2025
-
280 - Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data Mon, 30 Dec 2024
-
279 - Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine Mon, 23 Dec 2024
-
278 - Ep. 269 - Trends in VC Funds, Obesity Start-ups and More Mon, 16 Dec 2024
-
277 - Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal Mon, 09 Dec 2024
-
276 - Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts Mon, 02 Dec 2024
-
275 - Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update Mon, 25 Nov 2024
-
274 - Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals Mon, 18 Nov 2024
-
273 - Ep. 264 - Prepping for Trump & Alzheimer's Ethics Mon, 11 Nov 2024
-
272 - Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser Mon, 04 Nov 2024
-
271 - Ep. 262 - EGFR Case Study, FDA & Politics Mon, 28 Oct 2024
-
270 - Ep. 261 - China Summit: Reinventing Your China Strategy Wed, 23 Oct 2024
-
269 - Ep. 260 - VC Funds, New Chapter for MS, Wave's Data Mon, 21 Oct 2024
-
268 - Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA Mon, 14 Oct 2024
-
267 - Ep. 258 - Breaking the Bear: 4Q Public Markets Preview Mon, 07 Oct 2024
-
266 - Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update Mon, 30 Sep 2024
-
265 - Ep. 256 - ESMO Recap: Keeping TIGIT Alive, Rybrevant & Immunotherapy Anniversary Wed, 25 Sep 2024
-
264 - Ep. 255 - Pediatric PRVs, Biosecure & Novo's Obesity Miss Mon, 23 Sep 2024
-
263 - Ep. 254 - Takeaways from Grand Rounds 2024 Fri, 20 Sep 2024
-
262 - Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech Mon, 16 Sep 2024
-
261 - Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset Mon, 09 Sep 2024
-
260 - Ep. 251 - Eyes on the target: a Back to School Overview Fri, 06 Sep 2024
-
259 - Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery Wed, 04 Sep 2024
-
258 - Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update Mon, 26 Aug 2024
-
257 - Ep. 248 - Grand Rounds Preview: Eyes on the Target Thu, 22 Aug 2024
-
256 - Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School Mon, 19 Aug 2024
显示更多剧集
5